PERITONEAL DIALYSIS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/beea9cad6267b1f748640caf84207ba6.pdf

Abstract Title *

PERITONEAL DIALYSIS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Rita McGill rmcgill1@bsd.uchicago.edu University of Chicago Nephrology Chicago United States *

Co-author 2

Arlene Chapman achapman1@bsd.uchicago.edu University of Chicago Nephrology Chicago United States -

Co-author 3

Samantha Gunning sgunning@bsd.uchicago.edu University of Chicago Nephrology Chicago United States -

Co-author 4

Pranav Garimella pgarimella@health.ucsd.edu University of California San Diego Nephrology San Diego United States -

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Peritoneal dialysis (PD) is a convenient form of home dialysis. Patients with autosomal dominant polycystic kidney disease (ADPKD) are not always offered PD, due to concerns for organomegaly and hernias – although they are typically good candidates with few comorbid conditions. We examined PD outcomes among patients with ADPKD over the past 40 years.

Methods

Patients ≥ 30 years old with ADPKD between 1967-2021 were taken from US Renal Data System (USRDS) files. Patients were followed until death or 1/1/2023. A time-dependent covariate for treatment modality was constructed from treatment history files. Cox regression was used to calculate associations of each modality with patient death and non-preemptive transplant, with an interaction variable for year of incident end stage kidney disease (ESKD). Hazard ratios (HR) for PD and transplant were compared to HD as the reference category. Models were adjusted for age, sex, race, BMI, albumin, hemoglobin, and comorbid conditions. Data are shown for 1980-2021.

Results

Among 84,053 ADPKD patients, mean age was 56±12 years and 47% were female. Median follow-up was 82 (IQR: 37-154) months. PD exposure occurred in 27%. PD longevity was 20 (IQR=8-39) months. HR for mortality in PD compared to HD was 1.37(95%CI=1.29-1.44) in 1980, but decreased over time, with equivalence occurring between 1997-2000. After 2001, HR for mortality continue to decrease over time, and by 2021 HR for mortality in PD was 0.69 (95%CI=65-74), suggesting survival with PD had become superior (Fig. 1).

Figure 1 - Mortality

HR for non-preemptive transplant for PD compared to HD improved over time, becoming significant in 1994, and increasing to 1.24 (95%CI=1.18-1.31) by 2021 (Fig 2).

Conclusion

Use of PD among ADPKD patients currently demonstrates improved outcomes and has become increasingly advantageous, with increased patient survival and increased access to non-preemptive transplant.

Kewords